Faricimab, a recently approved bispecific antibody in China, targets both VEGF-A and angiopoietin-2 (Ang-2), offering a dual mechanism of action in the treatment of nAMD and diabetic macular edema. The gene discussed is ANGPT2; the disease is diabetic macular edema.